IL23A
ENSG00000110944
Target class
Secreted protein
Chromosome
12
Approved drugs
5
Clinical candidates (approved and in development)
8
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 8
- Chemical probe available
- No
- Target name
- IL23A
- Gene name
- Interleukin 23 subunit alpha
- Gene symbol
- IL23A
- Protein name
- Interleukin-23 subunit alpha (IL-23 subunit alpha) (IL-23-A) (Interleukin-23 subunit p19) (IL-23p19)
- SGRF
- IL23P19
- IL-23
- IL-23A
- P19
- Gene biotype
- Protein coding
- Gene family
- Interleukins
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 20
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 27.68
- Tissue specificity (Gini)
- 0.587
- Tissue specificity (tau)
- 0.961
- KEGG gene identifiers
- hsa:51561
- Protein interaction confidence
- 0.807324
- Protein interaction partners
- 34
- R-HSA-6785807
- R-HSA-9020933
- End position
- 56340410
- Start position
- 56334174
- Chromosome
- 12
- Strand
- Forward
- Secreted . Note=Secreted upon association with IL12B.
- Cytosol
Publication evidence
- PubMed 11114383
- Tissue specificity (tau)
- 0.961167
- Expression inequality (Gini)
- 0.587082
Expression in transcripts per million
- Testis
- 27.68
- Cells - EBV-transformed lymphocytes
- 9.91
- Spleen
- 3.81
- Pituitary
- 2.1
- Cells - Cultured fibroblasts
- 2.04
Expression in transcripts per million
- Testis27.68
- Cells - EBV-transformed lymphocytes9.91
- Spleen3.81
- Pituitary2.1
- Cells - Cultured fibroblasts2.04
- Small Intestine - Terminal Ileum1.97
- Lung1.67
- Esophagus - Mucosa1.6
- Minor Salivary Gland1.57
- Thyroid1.4
- Prostate1.26
- Kidney - Medulla1.18
- Cervix - Endocervix1.16
- Cervix - Ectocervix1.13
- Vagina1.11
- Fallopian Tube1.11
- Nerve - Tibial1.08
- Whole Blood1.06
- Liver1.06
- Ovary1
- Skin - Sun Exposed (Lower leg)0.97
- Breast - Mammary Tissue0.92
- Skin - Not Sun Exposed (Suprapubic)0.88
- Adipose - Subcutaneous0.87
- Adipose - Visceral (Omentum)0.87
And 29 more, listed on the interactive page.
- GO:0002230
- GO:0002827
- GO:0007259
- GO:0032693
- GO:0032725
- GO:0032729
- GO:0032733
- GO:0032735
- GO:0032740
- GO:0032760
- GO:0032816
- GO:0032819
- GO:0034105
- GO:0038155
- GO:0042102
- GO:0042104
- GO:0045672
- GO:0050729
- GO:0050829
- GO:0051135
- GO:0051142
- GO:0097696
- GO:1901224
- GO:0005576
- GO:0005788
- GO:0070743
- GO:0005125
- GO:0005515
- GO:0045519
Related records
Trials (501)
- A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants
- A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants
- A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
- A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis
- A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis
- A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
- A Long-term Extension Study of Ustekinumab in Pediatric Participants
- A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
- A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)
- A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
- A Multicentered Prospective Cohort Study of Chinese IBD Patients
- A Pharmacokinetic Study Comparing EG12014 and Herceptin (Trastuzumab) in Healthy Male Volunteers
- A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations
- A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Drugs (8)
- Brazikumab Interleukin-23 inhibitor
- Briakinumab Interleukin-23 inhibitor
- Ebdarokimab Interleukin-23 inhibitor
- Guselkumab Interleukin-23 inhibitor
- Mirikizumab Interleukin-23 inhibitor
- Risankizumab Interleukin-23 inhibitor
- Tildrakizumab Interleukin-23 inhibitor
- Ustekinumab Interleukin-23 inhibitor